InnoPharmax Balance Sheet Health
Financial Health criteria checks 6/6
InnoPharmax has a total shareholder equity of NT$433.7M and total debt of NT$10.0M, which brings its debt-to-equity ratio to 2.3%. Its total assets and total liabilities are NT$478.1M and NT$44.4M respectively.
Key information
2.3%
Debt to equity ratio
NT$10.00m
Debt
| Interest coverage ratio | n/a |
| Cash | NT$118.10m |
| Equity | NT$433.70m |
| Total liabilities | NT$44.37m |
| Total assets | NT$478.07m |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: 4172's short term assets (NT$157.3M) exceed its short term liabilities (NT$41.3M).
Long Term Liabilities: 4172's short term assets (NT$157.3M) exceed its long term liabilities (NT$3.1M).
Debt to Equity History and Analysis
Debt Level: 4172 has more cash than its total debt.
Reducing Debt: 4172's debt to equity ratio has reduced from 8.6% to 2.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 4172 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 4172 has sufficient cash runway for 1.8 years if free cash flow continues to grow at historical rates of 2.7% each year.